/
Oncology
Advanced or Metastatic Solid Tumors
126
Pipeline Programs↗
103
Active Trials↗
102
Companies Involved↗
Advanced or Metastatic Solid Tumors is a highly competitive landscape with 126 programs across 102 companies. The most active players are Ono Pharmaceutical Co. Ltd, Hanmi Pharmaceutical Company Limited, Olema Pharmaceuticals, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 176
Phase 242
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
104 of 113 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 113 classified programs, each share of the total. Modality classified for 96% of 126 pipeline programs.
Analysis
Trial Status
291
clinical trials
Completed116 · 40%
Recruiting64 · 22%
Terminated47 · 16%
Active, not recruiting25 · 9%
Unknown status17 · 6%
Not yet recruiting14 · 5%
Other8 · 3%
Clinical Trials
Trial Activity
291 trials
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)